NSPR Stock Overview
A medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
InspireMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.19 |
| 52 Week High | US$3.42 |
| 52 Week Low | US$1.81 |
| Beta | 1.0 |
| 1 Month Change | 10.38% |
| 3 Month Change | 20.38% |
| 1 Year Change | 21.31% |
| 3 Year Change | 24.85% |
| 5 Year Change | -76.15% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation
Jan 11
We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully
Jan 27We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate
Oct 05InspireMD: Revolutionizing The Field Of Vascular Stenting
Sep 20Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares
Feb 11Shareholder Returns
| NSPR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.1% | -0.3% | -2.2% |
| 1Y | 21.3% | 10.0% | 18.3% |
Return vs Industry: NSPR exceeded the US Medical Equipment industry which returned 11.1% over the past year.
Return vs Market: NSPR matched the US Market which returned 20.8% over the past year.
Price Volatility
| NSPR volatility | |
|---|---|
| NSPR Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NSPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NSPR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 80 | Marvin Slosman | www.inspiremd.com |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
InspireMD, Inc. Fundamentals Summary
| NSPR fundamental statistics | |
|---|---|
| Market cap | US$83.21m |
| Earnings (TTM) | -US$28.24m |
| Revenue (TTM) | US$6.82m |
12.2x
P/S Ratio-2.9x
P/E RatioIs NSPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSPR income statement (TTM) | |
|---|---|
| Revenue | US$6.82m |
| Cost of Revenue | US$5.28m |
| Gross Profit | US$1.54m |
| Other Expenses | US$29.78m |
| Earnings | -US$28.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 22.61% |
| Net Profit Margin | -413.96% |
| Debt/Equity Ratio | 0% |
How did NSPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 04:30 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InspireMD, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jose De Jesus Haresco | JMP Securities |